Analysts Issue Forecasts for PROF FY2028 Earnings

Profound Medical Corp. (NASDAQ:PROF) – Analysts at Raymond James issued their FY2028 earnings estimates for shares of Profound Medical in a report issued on Thursday, November 7th. Raymond James analyst R. Sarugaser expects that the company will post earnings per share of $2.96 for the year. The consensus estimate for Profound Medical’s current full-year earnings is ($1.10) per share.

Several other brokerages have also recently commented on PROF. Lake Street Capital assumed coverage on shares of Profound Medical in a report on Tuesday, July 23rd. They issued a “buy” rating and a $16.50 target price for the company. Stifel Nicolaus raised shares of Profound Medical from a “hold” rating to a “buy” rating and boosted their target price for the company from $9.00 to $12.00 in a research note on Tuesday, July 16th.

Profound Medical Stock Performance

Shares of NASDAQ PROF opened at $8.16 on Monday. Profound Medical has a 52-week low of $7.11 and a 52-week high of $11.69. The stock has a market capitalization of $201.24 million, a price-to-earnings ratio of -6.09 and a beta of 0.83. The company has a quick ratio of 7.42, a current ratio of 8.61 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $7.80 and its 200 day simple moving average is $8.45.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Raymond James Trust N.A. acquired a new position in Profound Medical in the second quarter worth approximately $88,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Profound Medical in the third quarter worth about $612,000. Thompson Davis & CO. Inc. boosted its position in Profound Medical by 9.0% during the second quarter. Thompson Davis & CO. Inc. now owns 74,800 shares of the company’s stock worth $628,000 after purchasing an additional 6,150 shares during the period. Royce & Associates LP boosted its holdings in shares of Profound Medical by 0.6% during the 3rd quarter. Royce & Associates LP now owns 569,298 shares of the company’s stock worth $4,529,000 after buying an additional 3,500 shares during the period. Finally, Gagnon Advisors LLC grew its position in shares of Profound Medical by 10.0% in the first quarter. Gagnon Advisors LLC now owns 747,226 shares of the company’s stock valued at $6,374,000 after purchasing an additional 67,930 shares during the last quarter. 47.86% of the stock is owned by institutional investors and hedge funds.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.